JMKX001899

Phase 3Small molecule

JJemincare

JMKX001899 is one of 98 small molecule programs targeting KRAS G12C Mutation. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

KRAS G12C MutationRecruiting

Single DoseNot yet recruiting

MetastaticNot yet recruiting

InteractionNot yet recruiting

KRAS G12C MutationPhase 1

Recruiting

Single DosePhase 1

Not yet recruiting

MetastaticPhase 3

Not yet recruiting

InteractionPhase 1

Not yet recruiting

Competition

Competitive Landscape

62 competitors in Interaction

#DrugCompanyPhaseTrials

Versed

CConrado Roberto Hoffmann Filho

Approved

91 2

Bayer Aspirin

Bayer

Approved

6 3

Robitussin

Pfizer

Phase 3

10 4

Rifadin

Sanofi

Phase 2

34 5

Sporanox

SSebela Pharmaceuticals Development LLC

Phase 2

77 6

Rifampicin

Boehringer Ingelheim

Phase 3

22 7

Crestor

AstraZeneca

Phase 1

61 8

Lanoxin

AAdvanz Pharma

Phase 1

47 9

Tegretol

Oxycontin

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 1Recruiting

KRAS G12C Mutation

NCT06946927

Q4 2029

Phase 3Not yet recruiting

Metastatic

NCT07242274

Clinical

Trials by Indication[1]

Single Dose1 trial

To Assess the Effects of Single Dose of JMKX001899 on QTc Interval in Healthy Subjects

Not yet recruiting·JJemincare·Phase 1·NCT06473948·27 enrolled

Metastatic1 trial

Phase 3 Trial of JMKX001899 Versus Docetaxel in Previously Treated Advanced or Metastatic KRAS G12C-Mutant NSCLC

Not yet recruiting·JJemincare·Phase 3·NCT07242274·472 enrolled

KRAS G12C Mutation1 trial

A Phase Ib Study of JMKX001899 in Combination With Other Therapies in Advanced NSCLC Harboring KRAS G12C Mutation

Recruiting·JJemincare·Phase 1·NCT06946927·72 enrolled

Interaction1 trial

Study to Evaluate the Drug-drug Interaction of JMKX001899 in Healthy Subjects

Not yet recruiting·JJemincare·Phase 1·NCT06348290·72 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for JMKX001899. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — JMKX001899 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for JMKX001899. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Jemincare company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: JJemincare

JMKX001899

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q4 2029

Trials by Indication[1]

Single Dose1 trial

Metastatic1 trial

KRAS G12C Mutation1 trial

Interaction1 trial

References

Drug Info

Quick Facts

Related News